NCT03158324: Phase IIa Dose-Expansion and Biomarker Study of OPB-111077

NCT03158324
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: BRAF, EGFR, HER2+, MET, PTEN, RET
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 2
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 21 Years to 99 Years (Adult, Senior)
Location of Metastases: 
Additional Notes: Patients must have oncogene-addicted cancers, examples include BRAF, EGFR, HER2+, MET, PTEN loss, RET- this is not an exhaustive list, other mutations may be eligible
Exclusions: 
https://ClinicalTrials.gov/show/NCT03158324

Comments are closed.

Up ↑